贝伐珠单抗联合紫杉醇和卡铂治疗复发性卵巢癌的临床效果

Clinical Effect of Bevacizumab Combined with Paclitaxel and Carboplatin in Treatment of Recurrent Ovarian Cancer

目的观察贝伐珠单抗联合紫杉醇和卡铂治疗复发性卵巢癌的效果。方法60例复发性卵巢癌患者随机分为两组,对照组给予紫杉醇联合卡铂治疗,观察组在对照组基础上给予贝伐珠单抗治疗,比较两组的炎性因子、VEGF、肿瘤标志物水平。结果治疗后,观察组的IL-2、INF-γ水平均高于对照组,IL-6、IL-10、VEGF以及肿瘤标志物水平均低于对照组(P<0.05)。结论贝伐珠单抗联合紫杉醇和卡铂可显著降低复发性卵巢癌患者的炎性因子、VEGF和肿瘤标志物水平。

Objective To observe the effect of bevacizumab combined with paclitaxel and carboplatin in treatment of recurrent ovarian cancer.Methods 60 patients with recurrent ovarian cancer were randomly divided into two groups.The control group was treated with paclitaxel combined with carboplatin,and the observation group was treated with bevacizumab on the basis of the control group.The levels of inflammatory factors,VEGF and tumor markers were compared between the two groups.Results After treatment,the levels of IL-2 and INF-γin the observation group were higher than those in the control group,and the levels of IL-6,IL-10,VEGF and tumor markers were lower than those in the control group(P<0.05).Conclusions Bevacizumab combined with paclitaxel and carboplatin can significantly reduce the levels of inflammatory factors,VEGF and tumor markers of patients with recurrent ovarian cancer.